Anavex Life Sciences Corp (AVXL)

[GrassyKnoll]

The FDA's' adaptive trial design is a major break from the traditional placebo control.

At it's core, it relies on the ability to have many different tests for indicating disease and the lack of it.
In each of those measured disease aspects, one can look for a dose response.
The Pk data will give a more accurate measurement of the actual dose that reaches the bloodstream of each patient, and be compared to the measured outcome of disease.
An upward sloping dose response curve for the group. In each disease category would add strength to the power of the analysis.

He has the PK data as the first reveal in the list, so it is coming soon, probably at the conference coming up.

It's gonna be really great. It is gonna be Huuuugh. And soon.
Now wether the market will get it, that is another story.
And the entrenched thinking at Big Pharma is another story.
I think this will shake them loose.